Skip to main content
SpringerLink
Log in

Attenuated Salmonella typhimurium with IL-2 Gene Reduces Pulmonary Metastases in Murine Osteosarcoma

  • Symposium: Selected Papers Presented at the 2007 Meeting of the Musculoskeletal Tumor Society
  • Published:
Clinical Orthopaedics and Related Research

Abstract

Historically, osteosarcoma has been a problematic metastatic disease, with 40–80% of patients developing pulmonary metastasis after primary tumor resection. Recent treatment advancements have reduced the occurrence of metastatic lesions to less than 30%. Using attenuated Salmonella typhimurium, we previously demonstrated regression in tumor burden in murine solid tumor and metastatic models. We established a murine model for metastatic osteosarcoma to determine the effect of treatment with a single oral dose of attenuated S. typhimurium with (SalpIL2) and without (Sal-NG) a gene for a truncated human interleukin-2. Female balb/c mice were administered 2 × 105 (ATCC K7M2) osteosarcoma cells via tail vein injection from culture and treated by oral gavage of Salmonella species 3 days later. Mice were harvested for splenic lymphocytes and tumor enumeration by intratracheal injection with India ink 21 days after injection. Treatment with attenuated SalpIL2 reduced pulmonary metastases in number and volume compared to saline controls. Furthermore, splenic natural killer cell populations were increased 93% with SalpIL2 and 114% with Sal-NG compared to nontreated groups. This pulmonary metastasis model demonstrates attenuated Salmonella typhimurium with human interleukin-2 reduced metastatic osteosarcoma in mice and confirm the need for further investigation into the immunologic properties of SalpIL2 as a possible treatment for metastatic osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4A–B
Fig. 5A–B

Similar content being viewed by others

References

  1. Barnett SJ, Soto LJ 3rd, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA. Attenuated salmonella typhimurium invades and decreases tumor burden in neuroblastoma. J Pediatr Surg. 2005;40:993–997; discussion 997-998.

    Article  PubMed  Google Scholar 

  2. Bermudes D, Low B, Pawelek J. Tumor-targeted salmonella. highly selective delivery vectors. Adv Exp Med Biol. 2000;465:57–63.

    PubMed  CAS  Google Scholar 

  3. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, Li Z, Luo X, King I, Zheng LM. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of salmonella typhimurium. J Infect Dis. 2000;181:1996–2002.

    Article  PubMed  CAS  Google Scholar 

  4. Curtiss R 3rd, Kelly SM. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun. 1987;55:3035–3043.

    PubMed  CAS  Google Scholar 

  5. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75:203–210.

    Article  PubMed  CAS  Google Scholar 

  6. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther. 2005;16:937–946.

    Article  PubMed  CAS  Google Scholar 

  7. Feltis BA, Miller JS, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Wells CL, Sielaff TD. Liver and circulating NK1.1(+)CD3(-) cells are increased in infection with attenuated salmonella typhimurium and are associated with reduced tumor in murine liver cancer. J Surg Res. 2002;107:101–107.

    PubMed  CAS  Google Scholar 

  8. Feltis BA, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Sielaff TD. Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral salmonella typhimurium in a model of mouse metastatic colon cancer. Dis Colon Rectum. 2002;45:1023–1028.

    Article  PubMed  Google Scholar 

  9. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19:292–315.

    Article  PubMed  CAS  Google Scholar 

  10. Foster L, Dall GF, Reid R, Wallace WH, Porter DE. Twentieth-century survival from osteosarcoma in childhood: Trends from 1933 to 2004. J Bone Joint Surg Br. 2007;89:1234–1238.

    Article  PubMed  CAS  Google Scholar 

  11. Harting MT, Blakely ML, Jaffe N, Cox CS Jr, Hayes-Jordan A, Benjamin RS, Raymond AK, Andrassy RJ, Lally KP. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41:194–199.

    Article  PubMed  Google Scholar 

  12. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000;18:261–271.

    Article  PubMed  CAS  Google Scholar 

  13. Lewis VO. What’s new in musculoskeletal oncology. J Bone Joint Surg Am. 2007;89:1399–1407.

    Article  PubMed  Google Scholar 

  14. Link MP, Gebhardt MC, Meyers PA, Pizzo PA, Poplack DG. Osteosarcoma. In: Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:1051–1089.

    Google Scholar 

  15. Loeffler M, Le’Negrate G, Krajewska M, Reed JC. Attenuated salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA. 2007;104:12879–12883.

    Article  PubMed  CAS  Google Scholar 

  16. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423–436.

    Article  PubMed  Google Scholar 

  17. Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Transcription factor fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA. 2003;100:8850–8855.

    Article  PubMed  CAS  Google Scholar 

  18. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–441.

    Article  PubMed  Google Scholar 

  19. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol. 2004;16:120–125.

    Article  PubMed  Google Scholar 

  20. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–2011.

    Article  PubMed  CAS  Google Scholar 

  21. Nakayama K., Kelly S.M., Curtiss R. III. Construction of an ASD+ expression cloning vector: Stable maintenance and high level expression of cloned genes in a salmonella vaccine strain. Nature Biotechnology. 1988;6:693–697.

    Article  CAS  Google Scholar 

  22. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. 2001;61:6178–6184.

    PubMed  CAS  Google Scholar 

  23. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y, Ritter G, Jager E, Nomura H, Kondo S, Tawara I, Kato T, Shiku H, Old LJ, Galan JE, Gnjatic S. In vivo antigen delivery by a salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006;116:1946–1954.

    Article  PubMed  CAS  Google Scholar 

  24. Pawelek JM, Low KB, Bermudes D. Tumor-targeted salmonella as a novel anticancer vector. Cancer Res. 1997;57:4537–4544.

    PubMed  CAS  Google Scholar 

  25. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg. 1988;208:121–135.

    Article  PubMed  CAS  Google Scholar 

  26. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474–84; discussion 484-5.

    Article  PubMed  CAS  Google Scholar 

  27. Saltzman DA, Heise CP, Hasz DE, Zebede M, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Attenuated salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother Radiopharm. 1996;11:145–153.

    PubMed  CAS  Google Scholar 

  28. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Patterns of hepatic and splenic colonization by an attenuated strain of salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent. Cancer Biother Radiopharm. 1997;12:37–45.

    Article  PubMed  CAS  Google Scholar 

  29. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Vigdorovich V, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Antitumor mechanisms of attenuated salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? J Pediatr Surg. 1997;32:301–306.

    Article  PubMed  CAS  Google Scholar 

  30. Schwinger W, Klass V, Benesch M, Lackner H, Dornbusch HJ, Sovinz P, Moser A, Schwantzer G, Urban C. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol. 2005;16:1199–1206.

    Article  PubMed  CAS  Google Scholar 

  31. Seibel NL, Krailo M, Chen Z, Healey J, Breitfeld PP, Drachtman R, Greffe B, Nachman J, Nadel H, Sato JK, Meyers PA, Reaman GH. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children’s cancer group (CCG) 7943. Cancer. 2007;109:1646–1653.

    Article  PubMed  CAS  Google Scholar 

  32. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood. 1993;81:1414–1423.

    PubMed  CAS  Google Scholar 

  33. Soto LJ 3rd, Sorenson BS, Kim AS, Feltis BA, Leonard AS, Saltzman DA. Attenuated salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J Pediatr Surg. 2003;38:1075–1079.

    Article  PubMed  Google Scholar 

  34. Soto LJ 3rd, Sorenson BS, Nelson BW, Solis SJ, Leonard AS, Saltzman DA. Preferential proliferation of attenuated salmonella typhimurium within neuroblastoma. J Pediatr Surg. 2004;39:937–40; discussion 937-40.

    Article  PubMed  Google Scholar 

  35. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20:142–152.

    Article  PubMed  Google Scholar 

  36. Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 2003;10:755–763.

    Article  PubMed  CAS  Google Scholar 

  37. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Isu K, Sugita T, Tomita K. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: The japanese musculoskeletal oncology group study. J Clin Oncol. 2002;20:3470–3477.

    Article  PubMed  Google Scholar 

  38. Xu C, Li ZS, Du YQ, Gong YF, Yang H, Sun B, Jin J. Construction of recombinant attenuated salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2. World J Gastroenterol. 2007;13:939–944.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank the Flow Cytometry Core Facility of the University of Minnesota Cancer Center, a comprehensive cancer center designated by the National Cancer Institute, supported in part by P30 CA77598. We also thank Dr. Robert Acton, Dr. Denis Clohisy, Dr. Robert Bulander, Dr. Karen Wasiluk, Karen McCulloch and Jerry Vincent for their support of this project. We also thank the University of Minnesota’s Cancer Center’s Histopathology Core for their slide preparation of histological samples. All experiments were approved by the University of Minnesota Institutional Animal Care and Uses Committee (number 0409A63728).

Author information

Authors and Affiliations

  1. Department of Surgery, University of Minnesota Medical School, 420 Delaware Street SE, MMC 195, Minneapolis, MN, 55455, USA

    Brent S. Sorenson BS, MS, Kaysie L. Banton MD, Natalie L. Frykman BS, Arnold S. Leonard MD, PhD & Daniel A. Saltzman MD, PhD

Authors
  1. Brent S. Sorenson BS, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaysie L. Banton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalie L. Frykman BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arnold S. Leonard MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniel A. Saltzman MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel A. Saltzman MD, PhD.

Additional information

Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. This project was paid for by the Arnold S. Leonard Cancer Research Fund and/or Department Chair.

Each author certifies that his or her institution has approved the animal protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.

About this article

Cite this article

Sorenson, B.S., Banton, K.L., Frykman, N.L. et al. Attenuated Salmonella typhimurium with IL-2 Gene Reduces Pulmonary Metastases in Murine Osteosarcoma. Clin Orthop Relat Res 466, 1285–1291 (2008). https://doi.org/10.1007/s11999-008-0243-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11999-008-0243-2

Keywords

Search

Navigation